# A Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects

> **NCT06883695** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 40 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** SHR-3045 Injection
- **DRUG:** SHR-3045 Placebo Injection

## Key facts

- **NCT ID:** NCT06883695
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-08
- **Primary completion:** 2025-06-17
- **Final completion:** 2025-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06883695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06883695, "A Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06883695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*